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Here we propose a carbon nanotube (CNT) field-effect transistor (FET) functionalized with aquaporin-4
(AQP4) extracellular loop peptides for the rapid detection of AQP4 antibody without pretreatment.
Neuromyelitis optica (NMO) is a rare disease of the central nerve system that affects the optic nerves and
the spinal cord. NMO-IgG, a serum antibody in patients, is highly specific for NMO and targets AQP4. We
synthesized AQP4 extracellular loop peptides, known as primary autoimmune target in NMO, and im-
mobilized them onto CNT-FET. The sensor showed p-type FET characteristics after the functionalization
of peptides. The sensor was able to detect antibody with a detection limit of 1 ng l1. Moreover, AQP4
antibody in human serum was detected without any pretreatment. These results indicate that the bio-
sensor can be used for rapid and simple detection of NMO antibody.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
Neuromyelitis optica (NMO, also known as Devic's disease) is a
severe and uncommon disease of the central nerve system (CNS)
that principally attacks the optic nerves and spinal cords (Win-
gerchuk et al., 1999, 2006). The symptoms of the disease, including
blindness and paralysis, are very serious. NMO is commonly con-
fused with multiple sclerosis (MS) because the symptoms are si-
milar. Since the treatments for the two diseases are different, an
accurate diagnosis in the early phase is important. In 2004, NMO-
IgG was found to be a highly specific biomarker in human blood
and enabled the differentiation of NMO and MS patients (Lennon
et al., 2004, 2005). This disease's specific antibody targets aqua-
porin-4 (AQP4), a transmembrane protein expressed in the CNS,
that regulates water transport in astrocytes and ependymal cells.
Various laboratory tests using AQP4 were developed for the de-
tection of AQP4 antibody with tissue-, cell- and protein-based
assays (Fazio et al., 2009; Hayakawa et al., 2008; Jarius et al., 2010;
Marnetto et al., 2009; McKeon et al., 2009; Paul et al., 2007;am for Bioengineering, Seoul
thpark@snu.ac.kr (T.H. Park).Takahashi et al., 2007; Waters et al., 2008). However, these
methods have the limitations such as low sensitivity and long
analytical time for diagnosis.
In a recent study, three extracellular loops (A, C and E) of AQP4
were found to contain disease-specific epitopes, which could be
used in an assay for the diagnosis of NMO (Iorio et al., 2013; Pisani
et al., 2011). In order to overcome the drawbacks of existing
methods, we propose a peptide-based Carbon nanotube (CNT)
biosensor for the rapid detection of AQP4 antibody in human
serum. A CNT-based field-effect transistor (FET) has been used for
the rapid detection of biological molecules with high sensitivity
(Jin et al., 2012; Lim et al., 2013, 2014; Park et al., 2012, 2014; Song
et al., 2014). CNTs have a large surface to volume ratio due to their
unique one-dimensional nanoscale structures. Thus, the electrical
properties of CNTs could be easily changed by adsorptions of
biomolecules onto their surfaces (Allen et al., 2007). We synthe-
sized AQP4 extracellular loop peptides and directly immobilized
them onto CNT channels. Using this biosensor, we could detect
AQP4 antibody, a biomarker of NMO disease, with a detection limit
of 1 ng l1. Furthermore, the sensor was able to detect the anti-
body without any pretreatment of the human serum.
Fig. 1. Schematic diagram showing the sensing mechanism of an AQP4 loop pep-
tide-based CNT-FET biosensor. Positively-charged AQP4 antibody binds with the
AQP4 extracellular loop peptides on CNTs, which gives a positive field-effect on the
FET and decreases its electric conductance.
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2.1. Synthesis of peptide
Three kinds of AQP4 extracellular loop peptides (A:
GGSENPLPVFFF, C: TPPSVVGGLGVTTVHGNLTAGFFF, E:
GNWENHWFFF) with purity higher than 95% were purchased from
Peptron (Korea). All peptides were dissolved and diluted at
1 mg ml1 with distilled water. The diluted peptide solution was
stored at 20 °C and thawed before used.
2.2. Fabrication of biosensor
The CNT-FET was fabricated via the photolithography process
as previously. Since a massive fabrication method provides the
uniform characteristics of devices, CNT-FETs were fabricated via
surface-programmed assembly method (Lee et al., 2006). Briefly,
photoresist (PR) was used to fabricate patterns for the channel
parts of FETs on a silicon oxide wafer. The region without patterns
were dipped into octadecyltrichlorosilane (OTS) solution (OTS:
Hexane¼1:400) for 7 min. The wafer was rinsed using acetone to
remove the PR patterns. The OTS-patterned water was incubated
in swCNT solution (0.05 mg/ml in dichlorobenzene) for 20 s. CNTs
were adsorbed specifically on the patterned SiO2 regions owing to
self-assembled OTS molecules on the surface. After the CNT pat-
terning process, Ti/Au (10/30 nm) electrodes were developed via
thermal evaporation. Finally, the insulating layer was fabricated
using PR (DNR) to prevent the electrodes from contacting the so-
lution. To immobilize the peptides, 1 ml of peptide solution was
placed on the CNT channel of the fabricated CNT-FET for 4 h. After
immobilization, unbound peptides were washed 3 times with
distilled water.
2.3. Characterization of peptide immobilization
The imaging of CNT channels were performed using AFM
(Asylum Research, USA) under ambient conditions. At first, the
pristine CNT channels were imaged in tapping mode with a scan
rate of 0.2 Hz. After the immobilization of the peptides, AFM
imaging of the CNT channels was performed in the same mode at
0.1 Hz to avoid undesired noise.
2.4. Electrical measurement
For the electrical signal measurement, 20 ml of PBS with pH
7.4 was added to the peptide-immobilized CNT channel. A 0.1 V
bias voltage was applied between the source and drain electrodes,
while the gate voltage was grounded. Current changes were
monitored with a 2636A Dual-channel system source meter in-
strument (Keithley, USA) and a MST 8000 probestation (MS TECH,
Korea).3. Results and discussion
3.1. Construction of peptide-based biosensor
Three kinds of AQP4 extracellular loop peptides were synthe-
sized, and three molecules of phenylalanine (Phe) were added to
the C-terminus in order to immobilize the synthesized peptides
onto CNTs via pi–pi interactions between CNTs and the aromatic
rings of Phe (Chen et al., 2001; Poenitzsch et al., 2007). In order to
have a maximal capacity for antibody sensing, sufficiently high
concentrations of the peptides were immobilized on the CNT
channels as a monolayer via self-assembly and unbounds were
washed away with distilled water. The fabricated CNT biosensorcould detect AQP4 antibody, which had a pI value of 9–10 and was
positively-charged in PBS of pH 7.4, with a decreased conductance.
Fig. 1 shows the sensing mechanism of the AQP4 loop peptide-
based biosensor.
To confirm the immobilization of the peptides, an atomic force
microscopy (AFM) image analysis was performed. Fig. 2a shows
the AFM images of the CNT channels before and after the im-
mobilization of three kinds of AQP4 extracellular loop peptides.
When we compared the height profiles of specific CNT regions, the
height was increased by 0.7173.13 nm with AQP4 loop A,
0.5672.9 nmwith AQP4 loop C and 1.472.9 nmwith AQP4 loop E
(Fig. 2b). These results show a successful immobilization of the
AQP4 extracellular loop peptides on CNT channels.
3.2. Electrical characteristic of biosensor
To evaluate the electrical property of the biosensor, the source–
drain current–voltage (ISD–VSD) of CNT channels were measured
(Fig. 3a). Although the resistance of the FET sensor was increased
from 6.55105 Ω to 1.54106 Ωwith AQP4 loop A, 6.57105 Ω to
1.23106 Ω with AQP4 loop C and 6.59105 Ω to 1.11106 Ω
with AQP4 loop E, the linearity of the curve was maintained before
and after the immobilization of the peptides. We constructed a
liquid-ion gated FET system with PBS (pH 7.4). The source–drain
current of the CNT channel was measured while increasing the
gate voltage (Fig. 3b). The current between the source and the
drain (ISD) decreased with an increasing gate voltage (VG), in-
dicating p-type FET behavior. These electrical characteristics in-
dicate that the sensor can detect positively-charged AQP4 anti-
body in PBS.
3.3. Detection of AQP4 antibody using biosensor
The sensing ability of this sensor was evaluated using anti-
bodies in PBS solution. A PBS droplet of 20 ml was added to the
peptide-immobilized CNT channel, and the sample solution con-
taining AQP4 antibody (ab46182, Abcam, UK) was injected. Fig. 4a
shows the real-time conductance of the sensor with concentra-
tions of AQP4 antibody ranging from 1 ng l1 to 1 mg l1. Each
AQP4 extracellular loop peptide-based sensor showed a dose-de-
pendent response. The sensor was able to detect AQP4 antibody at
a concentration as low as 1 ng l1 with AQP4 loop E. In our pre-
vious research for the detection of AQP4 antibody, nanovesicle-
based CNT biosensor showed the detection limit of 10 ng l1 an-
tibody (Park et al., 2014). The LOD was improved by ten-fold due to
the shortened distance between CNTs and antibody, since the
small size peptides were used. Fig. 4b shows the normalized
sensitivity of each peptide to different concentrations of AQP4
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Fig. 2. (a) AFM images of a CNT channel before and after the immobilization of AQP4 extracellular loop peptides. (b) Comparison of measured height profiles of CNT channels
before (blue line) and after (red line) the immobilization of peptides. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of this article.)
M. Son et al. / Biosensors and Bioelectronics 78 (2016) 87–91 89antibody. AQP4 loop E showed the highest sensitivity to AQP4
antibody among the three peptides. This result was attributed to
the different affinity of each peptide with the antibody and dif-
ferent lengths of the peptides on the CNT channel.
3.4. Detection of AQP4 antibody in human serum using biosensor
It was reported that the antibody level of NMO patients is
13.98475.981 g l1 (Chen et al., 2014). To evaluate the usability of
the sensor for the diagnosis of NMO, 1 g l1 of AQP4 antibody in
human serum (H4522, SIGMA, US) was tested. Serum samplescontaining AQP4 antibody were prepared to 1:105 dilution in PBS
to avoid a non-specific response (Lim et al., 2014). As shown in
Fig. 5a, the sensor did not respond to the human serum without
AQP4 antibody, but the conductance decreased when antibodies
were present in the serum samples. The RSD values were 8.33%
with AQP4 loop A, 23.08% with AQP4 loop C and 2.17% with AQP4
loop E (n¼3) (Fig. 5b). These results indicate that the sensor can be
effectively used for the rapid and easy diagnosis of NMO. This
biosensor is for a single-use. It was difficult to recover the current
signal after use, since the binding of antibody and peptide was not





















































































Fig. 3. (a) Current–voltage curves and (b) gate profiles of the CNT-FET before (blue line) and after (red line) the functionalization of AQP4 loop peptides. (For interpretation of
the references to color in this figure legend, the reader is referred to the web version of this article.)
M. Son et al. / Biosensors and Bioelectronics 78 (2016) 87–9190production of CNT-based sensor is available with the lithography
method and it requires only a small volume of peptide for the
functionalization. It also has advantages in simple and fast detec-
tion of antibody without complex pretreatment procedures.4. Conclusions
We developed a rapid sensor for the diagnosis of NMO using
peptide-based CNT-FET. AQP4 extracellular loop peptides, which
bind with the serum biomarker of NMO, were synthesized andthree molecules of Phe were added to the C-terminal for im-
mobilization on CNTs. The synthesized peptides were directly
immobilized onto CNT channels in the FET sensor. The constructed
biosensor showed p-type FET characteristics and could detect a
positively charged antibody. The sensor can detect 1 ng l1 of
AQP4 antibody with the AQP4 loop E peptide. Moreover, human
serum antibody was detected without any pretreatment. Due to its
high sensitivity and rapidity, this biosensor can be effectively used
as a simple and easy diagnostic method for NMO.
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Fig. 4. (a) Real-time responses of AQP4 loop peptide-based CNT-FETs to AQP4
antibody at concentrations ranging from 1 ng l1 to 1 mg l1. (b) Normalized sen-
sitivity of biosensors based on pristine CNTs (black line), CNTs functionalized with
AQP4 loop A (red line), C (green line) and E (blue line) to antibody. Error bars, s.e.m.
three replicates. (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article.)





























Fig. 5. (a) Real-time response to 1 g l1 of AQP4 antibody in 1/105-diluted human
serum. (b) Quantitative comparison of conductance change among AQP4 extra-
cellular loop A (red line), C (green line) and E (blue line). Error bars, s.e.m. three
replicates. (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
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